BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.

Abstract:

INTRODUCTION:BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monotherapy. A series of recent clinical trials have confirmed this hypothesis. AREAS COVERED:In this article, the biological rationale for both single and concomitant inhibitions of the MAPK pathway in BRAF mutant melanoma is provided. Moreover, available clinical data on the efficacy and toxicity of BRAF and MEK inhibition as single agents and in combination are extensively reviewed. EXPERT OPINION:Dual BRAF and MEK inhibition in advanced BRAF-mutated melanoma is superior to single inhibition in terms of efficacy without significant increase in toxicity. Therefore, BRAF plus MEK inhibition is expected to supersede single-agent BRAF inhibition in these patients in the near future.

authors

Richman J,Martin-Liberal J,Diem S,Larkin J

doi

10.1517/14656566.2015.1044971

subject

Has Abstract

pub_date

2015-06-01 00:00:00

pages

1285-97

issue

9

eissn

1465-6566

issn

1744-7666

journal_volume

16

pub_type

杂志文章,评审
  • Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.

    abstract::The adrenal steroidal hormone dehydroepiandrosterone (DHEA) has been studied as a potential pharmacological agent in the treatment of the autoimmune disease systemic lupus erythematosus (SLE). Both the endocrine effects (the ability to be converted peripherally to androgenic and oestrogenic sex steroids) and the immun...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.1.23

    authors: van Vollenhoven RF

    更新日期:2002-01-01 00:00:00

  • Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous system affecting both white matter and grey matter in the earliest phases of its course. The crucial role of neurodegeneration in disability progression in MS, regardless of white matter damage, has been confirm...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1434143

    authors: Pitteri M,Magliozzi R,Bajrami A,Camera V,Calabrese M

    更新日期:2018-03-01 00:00:00

  • New antiviral agents for the treatment of hepatitis C: ABT-450.

    abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.889116

    authors: Carrion AF,Gutierrez J,Martin P

    更新日期:2014-04-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • Asthma therapy during pregnancy.

    abstract::Numerous pregnant women suffer from asthma and the use of asthma medications during pregnancy may be a necessity. Although some information is known about the effects of asthma medications during pregnancy, there is still a significant amount of information to learn and particular attention is required when prescribin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.7.1019

    authors: Demoly P,Piette V,Daures JP

    更新日期:2003-07-01 00:00:00

  • Current options for the management of postmenopausal osteoporosis.

    abstract:INTRODUCTION:Osteoporosis is a well-recognized disease with severe consequences if left untreated. The prevention of osteoporosis-associated fractures should include fall prevention, calcium supplementation and life-style advice, as well as pharmacological therapy using agents with proven antifracture efficacy. AREAS ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618123

    authors: Lecart MP,Reginster JY

    更新日期:2011-11-01 00:00:00

  • Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.

    abstract:OBJECTIVE:Beta-lactamase producing bacteria present a major problem in treating lower respiratory tract infections. The objective of this study was to evaluate efficacy and safety of cefotaxime-sulbactam combination versus amoxicillin-clavulanic acid injection as an alternative therapeutic option for treatment of lower...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.9.16.2751

    authors: Pareek A,Kulkarni M,Daga S,Deshpande A,Chandurkar N

    更新日期:2008-11-01 00:00:00

  • Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.1.95

    authors: Barst RJ

    更新日期:2007-01-01 00:00:00

  • Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.

    abstract::Pancreatic cancer has one of the worst prognosis of any malignant disease. Systemic therapy is often administered because the disease is usually detected at advanced stages. Gemcitabine (Gemzar trade mark, Eli Lilly & Co.) has proven activity in the treatment of pancreatic cancer. Gemcitabine 1000 mg/m(2) was given on...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.4.581

    authors: Karasek P,Skacel T,Kocakova I,Bednarik O,Petruzelka L,Melichar B,Bustova I,Spurny V,Trason T

    更新日期:2003-04-01 00:00:00

  • On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524874

    authors: Samples LS,Graf SA

    更新日期:2018-10-01 00:00:00

  • Current status in the pharmacological management of interstitial cystitis.

    abstract::Interstitial cystitis is a clinical condition occurring predominantly in women characterised by irritative voiding symptoms in the form of urinary frequency, urgency and pain. Patient symptoms have the potential to significantly affect quality of life, posing a challenge to some to perform activities of daily living. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.1967

    authors: Lukban JC

    更新日期:2003-11-01 00:00:00

  • Pharmacotherapy of helminth infection.

    abstract:BACKGROUND:In the first decade of the 21st century, worm infections are still very common, especially--but not exclusively--in the developing world. OBJECTIVE:To review the current pharmacotherapy of the major trematode, cestode and nematode infections of humans. METHODS:A systematic search of the Cochrane Databank o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902722463

    authors: van den Enden E

    更新日期:2009-02-01 00:00:00

  • Botulinum toxin for the treatment of cervical dystonia.

    abstract::Cervical dystonia (CD) manifests clinically through involuntary spasms of neck muscles, producing abnormal head and neck movements and postures, which is often associated with pain. CD is the most common form of focal dystonia presenting to movement disorders clinics. Chemodenervation with botulinum toxin (BTX) has be...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.12.1985

    authors: Tintner R,Jankovic J

    更新日期:2001-12-01 00:00:00

  • Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.

    abstract:INTRODUCTION:Colorectal cancer (CRC) is the third most common cancer in the western world and also in Japan. The key factors in curing CRC are early detection, surgery and adequate adjuvant chemotherapy if needed. AREAS COVERED:Based on the results of following pivotal adjuvant trials, FOLFOX or XELOX are considered s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145665

    authors: Tsuji Y,Sugihara K

    更新日期:2016-01-01 00:00:00

  • Oxybutynin gel for the treatment of overactive bladder.

    abstract:INTRODUCTION:Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class are significantly more effective than placebo, they a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.688953

    authors: Gomelsky A,Dmochowski RR

    更新日期:2012-06-01 00:00:00

  • A review of the clinical efficacy and tolerability of almotriptan in acute migraine.

    abstract::Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.7.1157

    authors: Dodick DW

    更新日期:2003-07-01 00:00:00

  • Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.

    abstract::Despite the revolutionary introduction of antibiotic therapy in the post-World War II era, primary care physicians continue to struggle with the issue of optimal treatment strategies for bacterial infection and the growing problem of antimicrobial resistance. The aggressive use of potent agents as first-line therapy m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.229

    authors: Nicolau DP

    更新日期:2004-02-01 00:00:00

  • Recognition and effective management of autonomic dysreflexia in spinal cord injuries.

    abstract::Autonomic dysreflexia is a potentially life-threatening hypertensive medical emergency that occurs most often in spinal cord-injured individuals with spinal lesions at or above the mid-thoracic spinal cord level. It is a condition that remains poorly recognised outside of spinal cord injury centres, which may result i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.7.945

    authors: Khastgir J,Drake MJ,Abrams P

    更新日期:2007-05-01 00:00:00

  • Apomorphine in the treatment of Parkinson disease and other movement disorders.

    abstract:BACKGROUND:Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. OBJECTIVE:The clinical literature is summarized with particular focus on randomized controlled studies of apomo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902828344

    authors: Gunzler SA

    更新日期:2009-04-01 00:00:00

  • Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?

    abstract:INTRODUCTION:For the past three decades, carbapenems played a central role in our antibiotic armamentarium, trusted to effectively treat infections caused by drug-resistant bacteria. The utility of this class of antibiotics has been compromised by the emergence of resistance especially among Enterobacteriaceae. AREAS ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145658

    authors: Perez F,El Chakhtoura NG,Papp-Wallace KM,Wilson BM,Bonomo RA

    更新日期:2016-01-01 00:00:00

  • Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder.

    abstract:IMPORTANCE OF THE FIELD:It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for close to half of subjects with bip...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.490831

    authors: Fagiolini A,Casamassima F,Mostacciuolo W,Forgione R,Goracci A,Goldstein BI

    更新日期:2010-07-01 00:00:00

  • Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.

    abstract:INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.972364

    authors: Stirnimann G

    更新日期:2014-12-01 00:00:00

  • Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?

    abstract:INTRODUCTION:When estimating the cost-effectiveness or budget impact of chronic obstructive pulmonary disease (COPD) medication, it is common practice to use trial data for clinical inputs. However, such inputs do not always reflect the real-world situation. Previous reviews recognized the need for taking real-world da...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2021.1873953

    authors: Fens T,Zhou G,Postma MJ,van Puijenbroek EP,van Boven JFM

    更新日期:2021-01-13 00:00:00

  • Neoadjuvant or adjuvant chemotherapy in early breast cancer?

    abstract:INTRODUCTION:The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field. AREAS COVERED:Herein, the authors cover ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1746273

    authors: Montemurro F,Nuzzolese I,Ponzone R

    更新日期:2020-06-01 00:00:00

  • Evolving treatment strategies for chronic refractory angina.

    abstract::Chronic refractory angina is a term used to describe patients who, despite optimal medical therapy, have both angina and objective evidence of ischaemia. It is estimated that 5-15% of the 12 million patients with chronic angina in the US meet the criteria for having refractory angina. This review focuses on the follow...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.3.259

    authors: Yang EH,Barsness GW

    更新日期:2006-02-01 00:00:00

  • Paracetamol and asthma.

    abstract::Paracetamol (acetaminophen) is one of the over-the-counter analgesics that is used frequently for the self-management of some of the common disorders. There seems to be two types of relations between paracetamol and asthma - paracetamol intolerance leading to bronchospasm in analgesic-induced asthmatics; and the relat...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.1.13

    authors: Karakaya G,Kalyoncu AF

    更新日期:2003-01-01 00:00:00

  • Glatiramer acetate for the treatment of multiple sclerosis.

    abstract::Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.4.875

    authors: Wolinsky JS

    更新日期:2004-04-01 00:00:00

  • Itraconazole.

    abstract::Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.2.287

    authors: Piérard GE,Arrese JE,Piérard-Franchimont C

    更新日期:2000-01-01 00:00:00

  • The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.

    abstract:OBJECTIVE:The study investigated the efficacy and tolerability of teneligliptin co-administered to patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled by stable metformin monotherapy ≥ 1000 mg/day. METHODS:A total of 447 patients from 55 European centers who completed a 14-day screening and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2016.1190334

    authors: Bryson A,Jennings PE,Deak L,Paveliu FS,Lawson M

    更新日期:2016-07-01 00:00:00

  • Sustained release oral fampridine in the treatment of multiple sclerosis.

    abstract:BACKGROUND:Fampridine-SR is under submission as the first drug to be FDA approved with an indication specifically for multiple sclerosis symptoms. Compounded forms of the active agent of Fampridine-SR (4-aminopyridine) have been used in clinical practice for many years. Clinical trials have now been completed that demo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903075994

    authors: Kachuck NJ

    更新日期:2009-08-01 00:00:00